AMAALA
4.11.2020 13:32:11 CET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s north western coast, took to the seas with Monaco-based OceanoScientific on a two-week scientific expedition. The expedition was in line with AMAALA’s desire to measure and understand the impact of river water pollutants on human and sea life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201104005308/en/
The expedition was undertaken with a two-fold objective to determine the nature and density of the chemical compounds that affect the marine environment. It also placed a wider focus on the impact of chemical contaminants on the ocean and human health, and validates the applicability of the expedition’s sampling method, using a cost-effective research alternative with a zero-carbon emission vessel.
Over the course of two weeks, the crew collected water samples from various points within a triangle of 1,500 nautical miles in the western Mediterranean.
These samples were handed over to the Institut Français de Recherche pour l'Exploitation de la Mer (Ifremer) by the crew and AMAALA Chief Executive Officer Nicholas Naples and Chief Sustainability Officer Brendan Jack at the last port of call in La Seyne-sur-Mer, France. The scientists at the Ifremer, who advised on the scientific aspects of the undertaking, will now quantify and analyse the concentration of metals and elements such as cadmium, lead, nickel and mercury, all of which can alter the composition of the sea and affect the marine food chain.
The expedition and the results unearthed as part of its study will inform AMAALA’s own conservation efforts. The Red Sea and the Mediterranean Sea are neighbouring seas and part of one global ocean system where changes in one, create ripples in the other. With its vibrant coral gardens and rich underwater life, the Red Sea coast at AMAALA has a thriving ecosystem that the destination aims to preserve and nurture. To this end, it has forged partnerships with global marine conservation entities, including the Prince Albert II of Monaco Foundation, the Centre Scientifique de Monaco, and the Oceanographic Institute.
Commenting on the expedition, AMAALA Chief Executive Officer Nicholas Naples, said “We are proud to sponsor the OceanoScientific Expedition – it perfectly aligns with our goal to create a luxury destination that is a global leader in sustainable tourism. Being part of expeditions and studies like this, arms us with the deeper insight and scientific knowledge required to preserve and protect our local ecosystem, especially the Red Sea coral reefs. This expedition also illustrates our vision of creating experiences that brings diverse interests and cultures together.”
Yvan Griboval, circumnavigator explorer and member of the Yacht Club de Monaco, who led the expedition said, “While almost everyone has realised that plastic pollution is an appalling scourge on the ocean, we want to show that chemical contaminants - metallic and organic - that pollute the sea and poison the phytoplankton and plankton at the start of the food chain, are found in our dinner plates at the other end of the chain of life.”
The expedition was conducted on the specially commissioned AMAALA Explorer, a former record-breaking 110-foot racing maxi-catamaran that was converted into a scientific research ship with zero carbon emissions. It functioned as the expedition’s lodging and lab.
HSH Prince Albert II of Monaco on 15 October 2020 was on hand to bid the crew farewell from the marina of the Yacht Club de Monaco. The AMAALA Explorer made port calls in Porto Cervo, Italy; Barcelona, Spain; and La Seyne-sur-Mer, France where water samples were handed over to scientists, before returning to Monaco.
The vessel and expedition were skippered by Yvan Griboval, who worked with a team of scientists specialised in the study of organic contaminants, including an onboard Swedish marine scientist Linn Sekund and AMAALA Director of Sports Marc Archer.
A short documentary film about the expedition, in English and French, will be distributed in 2021, along with scientific results in late 2021 and scientific publication in late 2023.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
